3/4
07:51 am
athe
Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor [Yahoo! Finance]
Neutral
Report
Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor [Yahoo! Finance]
3/4
07:25 am
athe
Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor
Neutral
Report
Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor
3/2
08:01 am
athe
Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments [Yahoo! Finance]
Low
Report
Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments [Yahoo! Finance]
3/2
07:25 am
athe
Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments
Low
Report
Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments
2/14
06:24 am
athe
Alterity Therapeutics (NASDAQ:ATHE) was upgraded by analysts at Zacks Research to a "hold" rating.
Low
Report
Alterity Therapeutics (NASDAQ:ATHE) was upgraded by analysts at Zacks Research to a "hold" rating.
1/30
07:43 am
athe
Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update [Yahoo! Finance]
Medium
Report
Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update [Yahoo! Finance]
1/30
07:25 am
athe
Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update
Low
Report
Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update
1/21
07:25 am
athe
Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026
Medium
Report
Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026
12/17
08:05 am
athe
Alterity Therapeutics (NASDAQ:ATHE) is now covered by analysts at Canaccord Genuity Group Inc.. They set a "speculative buy" rating on the stock.
Medium
Report
Alterity Therapeutics (NASDAQ:ATHE) is now covered by analysts at Canaccord Genuity Group Inc.. They set a "speculative buy" rating on the stock.